Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy NovoCure stock

Learn how to easily invest in NovoCure stock.

NovoCure Limited
NASDAQ: NVCR - USD
$66.93
+ $2.52 ( + 3.90%)
MEDICAL INSTRUMENTS & SUPPLIES

NovoCure Limited is a medical instruments & supplies business based in the US. NovoCure shares (NVCR) are listed on the NASDAQ and all prices are listed in US Dollars. NovoCure employs 1,023 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in NovoCure

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NVCR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

NovoCure stock price (NASDAQ: NVCR)

Use our graph to track the performance of NVCR stocks over time.

NovoCure shares at a glance

Information last updated 2022-01-25.
Latest market close$64.41
52-week range$60.57 - $232.76
50-day moving average $85.56
200-day moving average $143.34
Wall St. target price$97.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.27

Buy NovoCure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NovoCure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NovoCure price performance over time

Historical closes compared with the close of $64.41 from 2022-01-25

1 week (2022-01-19) 0.36%
1 month (2021-12-23) -23.32%
3 months (2021-10-26) -43.26%
6 months (2021-07-26) -64.97%
1 year (2021-01-26) -60.86%
2 years (2020-01-24) -26.21%
3 years (2019-01-25) 29.36%
5 years (2017-01-26) 930.56%

Is NovoCure stock undervalued or overvalued?

Valuing NovoCure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NovoCure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NovoCure's EBITDA

NovoCure's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $225,000.

The EBITDA is a measure of a NovoCure's overall financial performance and is widely used to measure a its profitability.

NovoCure financials

Revenue TTM $545.8 million
Gross profit TTM $388.3 million
Return on assets TTM -0.68%
Return on equity TTM -7.49%
Profit margin -4.94%
Book value $3.98
Market capitalisation $7.4 billion

TTM: trailing 12 months

NovoCure share dividends

We're not expecting NovoCure to pay a dividend over the next 12 months.

NovoCure share price volatility

Over the last 12 months, NovoCure's shares have ranged in value from as little as $60.57 up to $232.76. A popular way to gauge a stock's volatility is its "beta".

NVCR.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NovoCure's is 0.8931. This would suggest that NovoCure's shares are less volatile than average (for this exchange).

NovoCure overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey. .

Frequently asked questions

What percentage of NovoCure is owned by insiders or institutions?
Currently 13.369% of NovoCure shares are held by insiders and 76.42% by institutions.
How many people work for NovoCure?
Latest data suggests 1,023 work at NovoCure.
When does the fiscal year end for NovoCure?
NovoCure's fiscal year ends in December.
Where is NovoCure based?
NovoCure's address is: No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
What is NovoCure's ISIN number?
NovoCure's international securities identification number is: JE00BYSS4X48
What is NovoCure's CUSIP number?
NovoCure's Committee on Uniform Securities Identification Procedures number is: G6674U108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site